Growth Stock Wire Investment Newsletter

 
Growth Stock Wire Investment Newsletter About Growth Stock Wire Frequently Asked Questions Growth Stock Wire Archives Contact Us Privacy Policy
Print Edition | Sponsored Link:

What's Left of the Great Asian Stock Mania
By Ian Davis

March 17 , 2008

From both a sociological and analytical point of view, the Japanese market is in the climactic stage of one of the great speculative booms of all time. The market is focusing on themes rather than specifics, like values or earnings.
Barton Biggs, famed investment analyst, in 1987

It took a few years of folks ignoring Barton Biggs before Japan was struck with one of the greatest stock market collapses in history.

Driven by the amazing industrial transformation that Japan began in the 1950s, the Japanese stock market (the Nikkei) rose 15-fold from 1970 to 1990. Real estate in Japan soared alongside the stock market. Notably, the property of the Emperor's Palace in Tokyo (which is smaller than Central Park) was said to be worth more than all the real estate in California. In addition, Japanese stocks were trading at hugely inflated multiples – 70-80 times earnings.

During the last year of the bull market, 1989, the Nikkei rose 29%. Then, starting on the first trading day of 1990, Japan's "guillotine" stage – the stage where stocks suffer huge losses in a short time – began. Over the next 30 months, the Nikkei fell 63%.

Then came the sandpaper stage... the stage where investors slowly bleed to death and finally sell their shares in disgust. Over the following 11 years, the Nikkei fell an additional 46.8%. Those years were an absolute nightmare for the average Japanese stock investor.

The following chart shows this spectacular rise and cataclysmic fall.

Is the Nikkei Finally Headed for a Recovery?

As you can see, after peaking in 1990, the Nikkei made new lows steadily for 13 years. Like all stock markets around the world, it rallied in 2003 and has been slammed in the past six months. So is the carnage finally over? Is Japan's stock market a contrarian's dream right now?

I'd like to say yes... After all, I get interested in any sector that's been pummeled for almost two decades. Currently, the Nikkei is in the midst of a pullback, and if the index can avoid falling to new lows, then the sandpaper stage may well be over.

But an investor's capital is too valuable to jump into a sector whose decline "may well be over."

The Yen Carry Trade: Not All It's Cracked Up to Be

Investing in Japanese Real Estate: Just Hit The Ground in Tokyo

There are a lot of value investors interested in Japanese stocks right now... but these stocks still aren't super cheap and they still haven't started a clear uptrend. The Datastream Japan index is selling for 20.8 times earnings and yielding 1.8%... Plus, the Nikkei is still around the level it was 10 years ago.

For you trend investors out there, I recommend waiting until Japan gets cheaper and proves itself through better price action before taking a position. Japan's "sandpaper stage" isn't over.

Good investing,

Ian Davis

Bear Stearns Gets Bailout, Skirts Bankruptcy
Bear Stearns Cos. shares plummeted a record 53 percent after the New York Federal Reserve and JPMorgan Chase & Co. stepped in to rescue the fifth-largest U.S. securities firm with emergency funding.

After denying earlier this week that access to capital was at risk, Bear Stearns said today that its cash position had "significantly deteriorated" in the past 24 hours. The New York Fed agreed to provide financing through JPMorgan for up to 28 days, the bank said in a statement today. Read on...

Barrick Chairman Calls "Commodity Supercycle"
Let's get one thing straight: Even at $1,000 (U.S.) an ounce, Peter Munk is still no gold bug.

The 80-year-old chairman of Barrick Gold Corp., who over the past quarter century has built his mining firm into the world's largest producer of the precious metal, says simply betting on a higher commodity price is no way to run a company. Read on...


Gold continues climb... Aurizon Mines, Great Basin Gold, Central Fund, Compania de Minas, Kinross Gold, Yamana, and Agnico-Eagle at new highs.

Bears Stearns leads financials down... JPMorgan, Goldman Sachs, Lehman Brothers, Citigroup, and Bear Stearns at new 52-week lows.

Barren pipelines strangle Big Pharma... Merck, Pfizer, AstraZeneca, Novartis, Sanofi-Aventis, and GlaxoSmithKline at new lows.

Last Change 52-Wk
S&P 500 1378.78 0.51% -4.87%
Oil (USO) 80.11 1.74% 57.39%
Gold (GLD) 93.75 1.09% 37.67%
Silver (SLV) 186.44 3.64% 26.84%
US Dollar 74.80 -1.06% 10.86%
Euro 1.497 0.98% 13.61%
VIX 21.88 -4.99% 96.23%
HUI 477.79 2.45% 32.05%
10-year yield 3.86% -0.04 -0.77
Company Sym Industry

ABN AMRO

ABN

bank

iS Silver

SLV

ETF

Cal-Maine Foods

CALM

eggs

Aurizon Mines

AZK

gold

Great Basin Gold

GBN

gold

Cabot Oil & Gas

COG

oil & gas

Banco de Chile

BCH

bank

Cross Timbers

CRT

oil & gas

CS Euro

FXE

ETF

Pan American

PAAS

gold & silver

BP Prudhoe Bay

BPT

oil & gas

Mechel

MTL

steel

Agnico-Eagle

AEM

gold

CS Japanese Yen

FXY

ETF

Compania de Minas

BVN

gold & silver

Central Fund

CEF

gold & silver

Yamana Gold

AUY

gold

streetTRACKS Gold

GLD

ETF

Kinross Gold

KGC

gold & silver

Chemical & Mining

SQM

chemicals

Highveld Steel

HSVLY

steel

Advertisement

Company Sym Industry

Bear Stearns

BSC

investment bank

Louisiana-Pacific

LPX

lumber

Merck

MRK

Big Pharma

First Marblehead

FMD

student lending

Quest

Q

telecom

Huaneng Power

HNP

utilities

CNA Financial

CNA

insurance

Goldman Sachs

GS

investment bank

CIT Group

CIT

credit svcs

Sony

SNE

electronics

Lehman Brothers

LEH

investment bank

Legg Mason

LM

asset mgmt

Pfizer

PFE

Big Pharma

Denny's

DENN

restaurants

JPMorgan

JPM

bank

Enbridge Energy

EEP

oil & gas

GlaxoSmithKline

GSK

Big Pharma

iS Broker-Dealers

IAI

ETF

AstraZeneca

AZN

Big Pharma

Best Buy

BBY

retail

Electronic Data

EDS

IT

Borders Group

BGP

books

Sepracor

SEPR

pharma

Sotheby's

BID

auctioneer

Bristol-Myers

BMY

Big Pharma

CBS

CBS

media

Enterprise GP

EPE

oil & gas

Gannett

GCI

newspapers

Eli Lilly

LLY

pharma

Novartis

NVS

Big Pharma

Progressive

PGR

insurance

Sanofi-Aventis

SNY

Big Pharma

Citigroup

C

bank

UBS

UBS

bank

Washington Post

WPO

newspapers

Home | About GSW | FAQ | GSW Archive | Privacy Policy | Contact Us

Customer Service: 1-888-261-2693 – Copyright 2010 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202